PDF herunterladen
Nervenheilkunde 2023; 42(07/08): 419-429
DOI: 10.1055/a-2103-7920
Schwerpunkt

Therapiemöglichkeiten der Depression nach Non-Response

Ein Update für die PraxisTreatment strategies for depression after non-responseAn update for clinical practice
Henrik Walter
1   Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
,
Raoul Haaf
1   Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
,
Stephan Köhler
1   Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin
› Institutsangaben
› Weitere Informationen
    Lizenzen und Reprints

ZUSAMMENFASSUNG

Die unipolare Depression stellt eine der häufigsten psychiatrischen Erkrankungen dar. Ein beträchtlicher Prozentsatz der Menschen, die an einer Depression leiden, erfahren trotz leitliniengerechter Ersttherapie mittels moderner psychopharmakologischer und/oder psychotherapeutischer Verfahren keine ausreichende Linderung ihrer Symptome. Die Therapie von Patienten mit einer „therapieresistenten“ oder „schwer zu behandelnden“ Depression stellt daher eine häufige Herausforderung in der alltäglichen Praxis dar. Anders als der Terminus „therapieresistent“ suggeriert, existieren jedoch eine Vielzahl an evidenzbasierten Therapieoptionen, die bei unzureichendem Ansprechen auf eine Standardtherapie mit Antidepressivum und Psychotherapie eingesetzt werden können. Mittels selektiver Literaturrecherche und unter Bezugnahme auf die kürzlich veröffentlichte 3. Version der Deutschen S3-Leitlinie zur Depression gibt vorliegender Artikel einen Überblick über weitere Therapieoptionen sowie Basismaßnahmen jenseits der Standardtherapien der unipolaren Depression.

ABSTRACT

Unipolar depression is one of the most common psychiatric disorders. A substantial percentage of people suffering from depression do not experience sufficient relief of their symptoms despite guideline-compliant initial therapy using modern psychopharmacological and/or psychotherapeutic methods. The treatment of patients with “treatment-resistant” or “difficult-to-treat” depression is therefore a frequent challenge in everyday practice. However, contrary to what the term “treatment-resistant” suggests, a variety of evidence-based treatment options exist, that can be considered when responses to standard antidepressant- and psychotherapy are insufficient. By means of a selective literature search and with reference to the recently published third version of the German S3 guideline on depression, this article provides an overview of further therapy options as well as basic measures beyond standard therapies for unipolar depression.

Schlüsselwörter

Behandlungsresistente Depression - depressive Störung - Pharmakotherapie - Psychotherapie - Hirnstimulation - neue Therapien

Key words

Treatment-resistant depression - depressive disorder - pharmacotherapy - psychotherapy - brain stimulation - new therapies


Publikationsverlauf

Artikel online veröffentlicht:
07. Juli 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Jacobi F, Höfler M, Strehle J. et al Psychische Störungen in der Allgemeinbevölkerung. Nervenarzt 2014; 85 (01) 77-87
    CrossrefPubMedGoogle Scholar
  • 2 Wittchen HU, Jacobi F, Rehm J. et al The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21 (09) 655-679
    CrossrefPubMedGoogle Scholar
  • 3 Moreno-Agostino D, Wu YT, Daskalopoulou C. et al Global trends in the prevalence and incidence of depression:a systematic review and meta-analysis. J Affect Disord 2021; 281: 235-243
    CrossrefPubMedGoogle Scholar
  • 4 Cipriani A, Furukawa TA, Salanti G. et al Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391 10128 1357-1366
    CrossrefPubMedGoogle Scholar
  • 5 Radisch J, Buchtemann D, Kastner D. et al A literature- and expert-based analysis of the outpatient treatment of depressive ill people in Germany Psychiatr Prax. 2013; 40 (05) 252-258
    PubMedGoogle Scholar
  • 6 Cuijpers P, Karyotaki E, Ciharova M. et al The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand 2021; 144 (03) 288-299
    CrossrefPubMedGoogle Scholar
  • 7 BÄK K, AWMF. et al. S3-Leitlinie Nationale VersorgungsLeitlinie Unipolare Depression. 3.1. Retrieved 23.05.2023. www.leitlinien.de/themen/depression Stand: 1.6.2023
    Google Scholar
  • 8 Bschor T, Bauer M, Adli M. Chronic and treatment resistant depression: diagnosis and stepwise therapy. Dtsch Arztebl Int 2014; 111 (45) 766-775
    CrossrefPubMedGoogle Scholar
  • 9 Thase M. Treatment-resistant depressions. Psychopharmacology: The fourth generation of progress 1995: 1081-1097
    PubMedGoogle Scholar
  • 10 Rush AJ, Trivedi MH, Wisniewski SR. et al Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. American Journal of Psychiatry 2006; 163 (11) 1905-1917
    CrossrefPubMedGoogle Scholar
  • 11 Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. Journal of Clinical Psychiatry 2006; 67 (09) 1412-1421
    CrossrefPubMedGoogle Scholar
  • 12 McAllister-Williams RH, Arango C, Blier P. et al The identification, assessment and management of difficult-to-treat depression: An international consensus statement. J Affect Disord 2020; 267: 264-282
    CrossrefPubMedGoogle Scholar
  • 13 Murphy JA, Byrne GJ. Prevalence and correlates of the proposed DSM-5 diagnosis of chronic depressive disorder. Journal of affective disorders 2012; 139 (02) 172-180
    CrossrefPubMedGoogle Scholar
  • 14 Selalmazidou AM, Bschor T. Depression: Niedrigschwellige Kardinalmaßnahmen als Basis jeder Behandlung. PSYCH up2date 2023; 17 (02) 117-130
    Artikel in Thieme ConnectGoogle Scholar
  • 15 Repple J, Opel N. Sport und körperliche Bewegung bei unipolarer Depression. Prävention, Therapie und neurobiologische Wirkmechanismen. Nervenarzt 2021; 92: 507-514
    CrossrefPubMedGoogle Scholar
  • 16 Haaf R, Machleid F, Köhler S.. Überblick über Digitale Gesundheitsanwendungen mit Fokus Depression. Nervenheilkunde 2023; 41: 430-437
    Google Scholar
  • 17 Kaczmarczyk M, Otte C. Pharmakotherapie depressiver Störungen. PSYCH up2date 2022; 16 (03) 229-250
    Artikel in Thieme ConnectGoogle Scholar
  • 18 Stastka K. Psychotherapie bei Depression. Psychopraxis. Neuropraxis 2016; 19: 186-191
    CrossrefGoogle Scholar
  • 19 Brakemeier EL, Jacobi F.. Verhaltenstherapie in der Praxis. Weinheim: Beltz; 2017
    Google Scholar
  • 20 Sinyor M, Schaffer A, Levitt A.. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review. Canadian Journal of Psychiatry 2010; 55 (03) 126-135
    CrossrefPubMedGoogle Scholar
  • 21 Hiemke C, Bergemann N, Clement HW. et al Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51 1–02 9-62
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 22 Debonnel G, Saint-André É, Hébert C. et al Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology 2007; 10 (01) 51-61
    CrossrefPubMedGoogle Scholar
  • 23 Adli M, Baethge A, Heinz N. et al Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. European archives of psychiatry and clinical neuroscience 2005; 255: 387-400
    CrossrefPubMedGoogle Scholar
  • 24 Bschor T, Kern H, Henssler J. et al Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. The Journal of Clinical Psychiatry 2016; 79 (01) 20627
    Google Scholar
  • 25 Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. The Canadian Journal of Psychiatry 2016; 61 (01) 29-43
    CrossrefPubMedGoogle Scholar
  • 26 Henssler J, Alexander D, Schwarzer G. et al Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry 2022; 79 (04) 300-312
    CrossrefPubMedGoogle Scholar
  • 27 Strawbridge R, Carter B, Marwood L. et al Augmentation therapies for treatment-resistant depression: systematic review and meta-analysis. The British Journal of Psychiatry 2019; 214 (01) 42-51
    CrossrefPubMedGoogle Scholar
  • 28 Crossley NA, Bauer M.. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007; 68 (06) 935-940
    CrossrefPubMedGoogle Scholar
  • 29 Bschor T, Bauer M. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 2006; 12 (23) 2985-2992
    CrossrefPubMedGoogle Scholar
  • 30 Nelson JC, Baumann P, Delucchi K. et al A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression. Journal of affective disorders 2014; 168: 269-275
    CrossrefPubMedGoogle Scholar
  • 31 Osterland SL, Adli M, Saritas T. et al Acute effects of lithium augmentation on the kidney in geriatric compared with non-geriatric patients with treatment-resistant depression. Acta Psychiatrica Scandinavica 2023; 147 (03) 267-275
    CrossrefPubMedGoogle Scholar
  • 32 Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998; 18 (02) 63-101
    CrossrefPubMedGoogle Scholar
  • 33 Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009; 166 (09) 980-991
    CrossrefPubMedGoogle Scholar
  • 34 Bauer M, Heinz A, Whybrow P. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Molecular psychiatry 2002; 07 (02) 140-156
    CrossrefPubMedGoogle Scholar
  • 35 Köberle U. Augmentation mit Schilddrüsenhormonen. Behandlungsmanual therapieresistente Depression. Pharmakotherapie-somatische Therapieverfahren–Psychotherapie. Stuttgart: Kohlhammer; 2008
    Google Scholar
  • 36 Caspar F.. Beziehungen und Probleme verstehen: Eine Einführung in die psychotherapeutische Plananalyse. Göttingen: Hogrefe; 2018
    CrossrefGoogle Scholar
  • 37 Hayes SC, Hofmann SG.. Process-based CBT: The science and core clinical competencies of cognitive behavioral therapy. New York: New Harbinger Publications; 2018
    Google Scholar
  • 38 van Bronswijk S, Moopen N, Beijers L. et al Effectiveness of psychotherapy for treatment-resistant depression: a meta-analysis and meta-regression. Psychological medicine 2019; 49 (03) 366-379
    CrossrefPubMedGoogle Scholar
  • 39 Schramm E, Elsaesser M, Domschke K. Review of dysthymia and persistent depressive disorder: history, correlates, and clinical implications. The Lancet Psychiatry 2020; 07 (09) 801-812
    CrossrefPubMedGoogle Scholar
  • 40 Köhler SJ, Baumann N, Baghai TC. Differences between chronic and nonchronic depression: Systematic review and implications for treatment. Depression and Anxiety 2019; 36 (01) 18-30
    CrossrefPubMedGoogle Scholar
  • 41 McCullough Jr JP, Schramm E, Penberthy JK. CBASP as a distinctive treatment for persistent depressive disorder: distinctive features. London: Routledge; 2014
    CrossrefGoogle Scholar
  • 42 Guhn A, Köhler S J, Klein J. CBASP – eine evidenzbasierte und praxisorientierte Einführung. PSYCH up2date 2022; 16(4)
    Google Scholar
  • 43 Brakemeier EL.. Cognitive Behavioral Analysis System of Psychotherapy (CBASP) vs. Behavioral Activation (BA) bei stationären Patienten mit persistierend depressiven und therapieresistenten Störungen: Wirksamkeit, Moderatoren und Mediatoren der Veränderung. https://psychologie.uni-greifswald.de/changepdd Stand: 1.6.2023
    Google Scholar
  • 44 Buthut M, Haslacher D, Soekadar SR. Behandlung depressiver Störungen mittels nicht-invasiver Neuromodulation. Nervenheilkunde 2023; 41: 438-448
    Google Scholar
  • 45 Group UER.Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. The Lancet 2003; 361 9360 799-808
    CrossrefPubMedGoogle Scholar
  • 46 Weiner RD, Reti IM. Key updates in the clinical application of electroconvulsive therapy. International Review of Psychiatry 2017; 29 (02) 54-62
    CrossrefPubMedGoogle Scholar
  • 47 Elias A, Phutane VH, Clarke S. et al Electroconvulsive therapy in the continuation and maintenance treatment of depression: Systematic review and meta-analyses. Australian & New Zealand Journal of Psychiatry 2018; 52 (05) 415-424
    CrossrefPubMedGoogle Scholar
  • 48 Sonmez AI, Camsari DD, Nadakumar AL. Accelerated TMS for Depression: A systematic review and meta-analysis. Psychiatry Res 2019; 273: 770-781
    CrossrefPubMedGoogle Scholar
  • 49 Huang YZ, Edwards MJ, Rounis E. et al Theta burst stimulation of the human motor cortex. Neuron 2005; 45 (02) 201-6
    CrossrefPubMedGoogle Scholar
  • 50 Cole EJ, Phillips AL, Bentzley BS. et al Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. Am J Psychiatry 2022; 179 (02) 132-141
    CrossrefPubMedGoogle Scholar
  • 51 Reif-Leonhard C, Reif A, Baune B. et al Vagusnervstimulation bei schwer zu behandelnden Depressionen. Der Nervenarzt 2022; 93 (09) 921-930
    CrossrefPubMedGoogle Scholar
  • 52 Aaronson ST, Sears P, Ruvuna F. et al A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. American Journal of Psychiatry 2017; 174 (07) 640-648
    CrossrefPubMedGoogle Scholar
  • 53 Kisely SA, Li A, Warren N. et al A systematic review and meta-analysis of deep brain stimulation for depression. Depression and Anxiety 2018; 35: 468-480
    CrossrefPubMedGoogle Scholar
  • 54 Coenen VA, Bewernick BH, Kayser S. et al Superolateral medial forebrain bundle deep brain stimulation in major depression: A gateway trial. Neuropsychopharmacology 2019; 44 (07) 1224-1232
    CrossrefPubMedGoogle Scholar
  • 55 Dougherty D, Rezai A, Carpenter L. et al A randomized sham controlled trial of deep brain stimulation of the ventral capsule/ventral striatum for chronic treatment-resistant depression. Biological Psychiatry 2015; 78: 240-248
    CrossrefPubMedGoogle Scholar
  • 56 Holtzheimer PE, Husain MM, Lisanby SH. et al Subcallosal cingulate deep brain stimulation for treatment-resistant depression: a multisite, randomised, sham-controlled trial. The Lancet Psychiatry 2017; 04 (11) 839-849
    CrossrefPubMedGoogle Scholar
  • 57 Müller S, van Oosterhout A, Bervoets C. et al Concerns About Psychiatric Neurosurgery and How They Can Be Overcome: Recommendations for Responsible Research. Neuroethics 2022; 15: 6
    CrossrefGoogle Scholar
  • 58 Papakostas GI, Salloum NC, Hock RS. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis. The Journal of Clinical Psychiatry 2020; 81 (04) 19r12889
    CrossrefPubMedGoogle Scholar
  • 59 Daly EJ, Trivedi MH, Janik A. et al Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76 (09) 893-903
    CrossrefPubMedGoogle Scholar
  • 60 Fedgchin M, Trivedi M, Daly EJ. et al Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression: results of a randomized, double-blind, active-controlled study (TRANSFORM-1). International Journal of Neuropsychopharmacology 2019; 22 (10) 616-630
    CrossrefPubMedGoogle Scholar
  • 61 Nichols DE. Chemistry and structure–activity relationships of psychedelics. Behavioral Neurobiology of Psychedelic Drugs 2018: 1-43
    PubMedGoogle Scholar
  • 62 Becher, et al Psychedelika-gestützte Psychotherapie in der Behandlung depressiver Störungen. Ein Blick auf die Vergangenheit, den Stand der Forschung und die Zukunft. Nervenheilkunde 2023; 41: 450-458
    Google Scholar
  • 63 Ko K, Knight G, Rucker JJ. et al Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Frontiers in psychiatry 2022: 13
    PubMedGoogle Scholar
  • 64 Kupfer DJ. Management of Recurrent Depression. J ClinPsychiatry 1993; 54: 29-33
    Google Scholar